| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Bradycardia | D001919 | 13 associated lipids |
| Endometriosis | D004715 | 29 associated lipids |
| Myocardial Infarction | D009203 | 21 associated lipids |
| Proteinuria | D011507 | 30 associated lipids |
| Drug Hypersensitivity | D004342 | 20 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Fractures, Open | D005597 | 3 associated lipids |
| Arthritis, Infectious | D001170 | 8 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ednie LM et al. | Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). | 1997 | Antimicrob. Agents Chemother. | pmid:9303406 |
| Visalli MA et al. | Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. | 1997 | Antimicrob. Agents Chemother. | pmid:9303375 |
| Versalovic J et al. | Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. | 1997 | J. Antimicrob. Chemother. | pmid:9301997 |
| López-Brea M et al. | Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. | 1997 | J. Antimicrob. Chemother. | pmid:9301996 |
| Stone GG et al. | PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial. | 1997 | J. Antimicrob. Chemother. | pmid:9301991 |
| Irie Y et al. | Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. | 1997 | J. Antimicrob. Chemother. | pmid:9301989 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. | 1997 | Gut | pmid:9301496 |
| Laberge P and Martineau P | Clarithromycin-induced digoxin intoxication. | 1997 | Ann Pharmacother | pmid:9296239 |
| Recker MW and Kier KL | Potential interaction between clarithromycin and warfarin. | 1997 | Ann Pharmacother | pmid:9296238 |
| Visalli MA et al. | Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. | 1997 | Diagn. Microbiol. Infect. Dis. | pmid:9294703 |
| Akaki T et al. | [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. | 1997 | Kekkaku | pmid:9293712 |
| Kearsley NL et al. | Comparison of clarithromycin suspension and amoxycillin syrup for the treatment of children with pharyngitis and/or tonsillitis. | 1997 Apr-May | Br J Clin Pract | pmid:9293051 |
| Sekkarie MA | Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. | 1997 | Am. J. Kidney Dis. | pmid:9292575 |
| Kobler E et al. | [Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease]. | 1997 | Schweiz Med Wochenschr Suppl | pmid:9289833 |
| Tan WC et al. | Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis. | 1997 | Int. J. Clin. Pract. | pmid:9287260 |
| Matsukura N | [Two step therapy for education of Helicobacter pylori]. | 1997 | Nihon Shokakibyo Gakkai Zasshi | pmid:9284449 |
| Hirakawa T | [Diagnosis and treatment of Helicobacter pylori]. | 1997 | Nippon Ika Daigaku Zasshi | pmid:9283206 |
| Lam SK et al. | Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. | 1997 | Gut | pmid:9274470 |
| Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. | 1997 | Gut | pmid:9274464 | |
| Marone P et al. | Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. | 1997 | J Chemother | pmid:9269603 |
| Uemura N et al. | Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. | 1997 | Cancer Epidemiol. Biomarkers Prev. | pmid:9264278 |
| Sato K et al. | [Anti-Mycobacterium avium complex activities of KRM-1648, clarithromycin and levofloxacin in 7HSF medium at peak or average blood concentrations after their oral administration of clinical dosages]. | 1997 | Kekkaku | pmid:9259129 |
| Shibata K et al. | Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. | 1997 | Jpn J Antibiot | pmid:9258741 |
| Polis MA et al. | Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. | 1997 | Antimicrob. Agents Chemother. | pmid:9257746 |
| Rouse MS et al. | Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. | 1997 | Antimicrob. Agents Chemother. | pmid:9257739 |
| Böttger EC et al. | Prophylaxis of mycobacterial infection and acquired drug resistance. | 1997 | J. Antimicrob. Chemother. | pmid:9249224 |
| Fuursted K | Evaluation of the post-antibiotic effect of six anti-mycobacterial agents against Mycobacterium avium by the Bactec radiometric method. | 1997 | J. Antimicrob. Chemother. | pmid:9249202 |
| Gisbert JP et al. | Unhealed duodenal ulcers despite Helicobacter pylori eradication. | 1997 | Scand. J. Gastroenterol. | pmid:9246702 |
| Saluja A et al. | A surgical wound infection due to Mycobacterium chelonae successfully treated with clarithromycin. | 1997 | Dermatol Surg | pmid:9236871 |
| Sano M et al. | [A clinical study on combination therapy of antimicrobial agents for complicated urinary tract infection--with special reference to combination with clarithromycin]. | 1997 | Nippon Hinyokika Gakkai Zasshi | pmid:9234616 |
| Hoffman JS | Pharmacological therapy of Helicobacter pylori infection. | 1997 | Semin. Gastrointest. Dis. | pmid:9232728 |
| Matsumoto T et al. | Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori. | 1997 | Lancet | pmid:9228971 |
| Svoboda P et al. | Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. | 1997 May-Jun | Hepatogastroenterology | pmid:9222709 |
| Gisbert JP et al. | [What is the current role of clarithromycin in the eradication of Helicobacter pylori?]. | 1997 | Rev Esp Enferm Dig | pmid:9221019 |
| Nawarskas JJ et al. | Digoxin toxicity secondary to clarithromycin therapy. | 1997 Jul-Aug | Ann Pharmacother | pmid:9220047 |
| Grunden JW and Fisher KA | Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. | 1997 Jul-Aug | Ann Pharmacother | pmid:9220046 |
| Hoppe JE and Tschirner T | Comparison of Etest and agar dilution for testing the activity of three macrolides against Bordetella parapertussis. | 1997 | Diagn. Microbiol. Infect. Dis. | pmid:9218920 |
| O'Brien B et al. | Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. | 1997 May-Jun | Can. J. Gastroenterol. | pmid:9218858 |
| Best LM et al. | Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. | 1997 May-Jun | Can. J. Gastroenterol. | pmid:9218854 |
| Lim AG et al. | Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. | 1997 | Aliment. Pharmacol. Ther. | pmid:9218079 |
| Chimura T | [Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection]. | 1997 | Jpn J Antibiot | pmid:9212369 |
| Meyer JM et al. | In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. | 1997 | Antimicrob. Agents Chemother. | pmid:9210696 |
| Mikasa K et al. | Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. | 1997 Jul-Aug | Chemotherapy | pmid:9209786 |
| Kim MJ et al. | Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment. | 1997 | Gastroenterology | pmid:9207259 |
| Verhaegen J et al. | Impredictable susceptibility for cephalosporins in penicillin resistant Streptococcus pneumoniae. | 1997 | Acta Clin Belg | pmid:9204588 |
| Götz JM et al. | Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dismutases. | 1997 | Gut | pmid:9203935 |
| Kato S et al. | Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. | 1997 | Pediatrics | pmid:9200377 |
| Marignani M et al. | Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. | 1997 | Scand. J. Gastroenterol. | pmid:9200297 |
| Fréhel C et al. | The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin. | 1997 | Infect. Immun. | pmid:9199452 |
| Lo WC et al. | Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. | 1997 | Zhonghua Yi Xue Za Zhi (Taipei) | pmid:9198292 |